All IndicationsPhase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 2
SARS-CoV-2 Infection
1
Companies
8
Drug Programs
7
Phase 3
0
Upcoming PDUFAs
Competitors
BNTX
BioNTech SE
Seasonal Inactivated Influenza Vaccine
BNTX
BioNTech SE
BNT162b1
BNTX
BioNTech SE
BNT162b2 (Omi XBB.1.5)
BNTX
BioNTech SE
BNT162b2
BNTX
BioNTech SE
BNT162b2 OMI
BNTX
BioNTech SE
BNT162b5 Bivalent (WT/OMI BA.2)
BNTX
BioNTech SE
BNT162b2.B.1.351
BNTX
BioNTech SE
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| BNTX BioNTech SE | Seasonal Inactivated Influenza Vaccine | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b1 | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b2 (Omi XBB.1.5) | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b2 | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b2 OMI | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b5 Bivalent (WT/OMI BA.2) | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b2.B.1.351 | Phase 3 | — | — | — |
| BNTX BioNTech SE | Multivalent BNT162b2 (B.1.1.7 + B.1.617.2) | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
7
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.